For US residents only.

How Treatment May Help

KISQALI® (ribociclib) + HORMONE THERAPY OR FULVESTRANT

Live Longer Without Disease Progression

KISQALI® (ribociclib) along with hormone therapy (eg, letrozole or anastrozole) or fulvestrant can be a treatment option for a wide range of women with HR+, HER2-metastatic breast cancer. Here are some proven results that show how KISQALI may help.

KISQALI + letrozole or anastrozole + goserelin

In a clinical trial dedicated exclusively to younger women, 495 patients were treated with KISQALI + hormone therapy (eg, letrozole or anastrozole) or hormone therapy alone. KISQALI + hormone therapy helped premenopausal women live longer without disease progression.

2 years of progression-free survival from start of treatment
Proven to shrink tumors

KISQALI + letrozole or anastrozole + goserelin worked together to shrink tumors in women who had measurable tumors.

51% of women taking KISQALI + letrozole or anastrozole +goserelin had tumors that shrank or disappeared vs. 36% of women taking letrozole or anastrozole + goserelin

*48% of women taking KISQALI + letrozole or anastrozole + goserelin saw their tumors shrink in size vs 34% of those taking letrozole or anastrozole + goserelin. And 3% of women taking KISQALI + letrozole or anastrozole + goserelin had their tumors completely disappear vs 3% of those taking letrozole or anastrozole + goserelin.

KISQALI + fulvestrant

KISQALI is used along with the medicine fulvestrant in postmenopausal women who are either newly diagnosed with HR+, HER2- metastatic breast cancer, or who have already received hormone therapy.

20.5 months of progression-free survival with KISQALI + fulvestrant
Proven to shrink tumors

In a clinical trial, 726 patients were treated with either KISQALI + fulvestrant or fulvestrant alone. KISQALI + fulvestrant worked together to shrink tumors in women who had measurable tumors.

40.9% of women taking KISQALI + fulvestrant had tumors that shrank or disappeared vs. 28.7% of women taking fulvestrant alone

*39% of women taking KISQALI + fulvestrant saw their tumors shrink in size vs 29% of those taking fulvestrant alone. And 2% of women taking KISQALI + fulvestrant had their tumors completely disappear vs 0% of those taking fulvestrant alone.

KISQALI + letrozole

KISQALI works in combination with a hormone therapy to delay the progression of metastatic breast cancer in postmenopausal women. In a clinical trial of 668 women, KISQALI + letrozole reduced the risk of disease progression by 44% vs letrozole alone. At the time of this analysis, more than half of women taking KISQALI + letrozole remained alive and progression free.

2+ years of progression-free survival with KISQALI + letrozole
Proven to shrink tumors

KISQALI and letrozole worked together to shrink tumors in women who had measurable tumors.

52% of women taking KISQALI + letrozole had tumors that shrank or disappeared vs. 37.1% of women taking letrozole alone
3 out of 4 women saw tumor shrinkage at the first trial check-in (observed 8 weeks after starting treatment).

50% of women taking KISQALI + letrozole saw their tumors shrink in size vs 35% of those taking letrozole alone. And 3% of women taking KISQALI + letrozole had their tumors completely disappear vs 2% of those taking letrozole alone.

The Face of Metastatic Breast Cancer

Watch the KISQALI® (ribociclib) video to meet three women who are representing the experience of living with HR+, HER2- metastatic breast cancer. Listen as they discuss the importance of advocating for yourself, and learn about proven treatment results seen with KISQALI.